Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Strotmann

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical and Translational Science|October 24, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enablerHong Lu, Lena Klopp-Schulze, Jatinder Kaur Mukker, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical and Translational Science|October 24, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enablerHong Lu, Lena Klopp-Schulze, Jatinder Kaur Mukker, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Pageof 3